NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, with inhibition of NF-κB and Bcr-Abl, pristimerin is effective in vitro and in vivo against imatinib-resistant chronic myelogenous leukemia cells (Lu et al., 2010).